DALLAS, April 4, 2008 /PRNewswire/ -- Data from five studies sponsored by Ortho Biotech Products, L.P. will be presented at the National Kidney Foundation (NKF) 2008 Spring Clinical Meetings from April 2 - 6, 2008; three utilization studies involve PROCRIT(R) (Epoetin alfa).
The data include studies that compare drug utilization patterns and costs of PROCRIT (EPO) and darbepoetin alfa (DARB), evaluate medical costs related to chronic kidney disease (CKD) patients with hypertension or diabetes, and show the impact on hemoglobin (Hb) control using a software-based management tool. These retrospective analyses used data from actual clinical practice.
Data on Drug Utilization Patterns and Costs of Epoetin Alfa and
-- Abstract: Assessment of Drug Utilization Patterns and Costs for
Erythropoietic Stimulating Agents in Patients with Chronic Kidney
Patrick Lefebvre, M.A., Groupe d'analyse, Ltee, Montreal, Quebec,
A retrospective analysis of medical claims was conducted using the
Ingenix Impact National Managed Care Database to examine recent EPO and
DARB treatment patterns and corresponding drug costs in newly-initiated
CKD patients treated with EPO (n=1,110) or DARB (n=723) not receiving
dialysis. Mean cumulative dose was used to calculate drug costs based
on October 2007 wholesale acquisition unit prices.
-- Abstract: Drug Utilization and Cost Considerations of Predialysis
Chronic Kidney Disease Patients Receiving Erythropoietic Stimulating
Agents Through Pharmacy Benefits
Francois Laliberte, M.A., Groupe d'analyse, Ltee, Montreal, Quebec,
A retrospective analysis of pharmacy claims using the PharMetrics
Patient-Centric Database, which represents approximately 85 managed
healthcare plans, was conducted to compare drug utilization patterns
|SOURCE Ortho Biotech Products, L.P.|
Copyright©2008 PR Newswire.
All rights reserved